When the FDA authorized JUUL2 on August 28, the headline wasn't the device — it was the data. Adults using the menthol-flavored pod were 28.4% to 49.3% likely to completely switch from cigarettes within six weeks, compared to 19.9%–34.6% for the tobacco-flavored pod. That's not a marginal difference. The menthol pod's floor exceeds the tobacco pod's ceiling.

The Science in Plain English

Here's what the FDA actually reviewed. JUUL Labs submitted a 6-week actual-use study — a prospective, real-world trial designed to evaluate how adult smokers behave when given a vaping product with no instructions to quit. The study, published in the Interactive Journal of Medical Research in March 2025, recruited 1,160 US adults who smoked cigarettes daily and were "predominantly not ready to quit" (only 1% planned to stop within 30 days).

Participants were given JUUL2 devices with 18 mg/mL nicotine pods in one of five flavors and followed for six weeks. No cessation counseling. No quit goals. No behavioral support. Just the product and their own choices.

The results were striking:

• Past-7-day switching (no cigarettes in the past week) ranged from 38.2% to 47.3% across flavor groups at week 6
• Past-30-day switching (no cigarettes in the past month) ranged from 24.3% to 33.9%
• Menthol advantage: Participants using the three menthol-flavored pods had significantly higher 30-day switching rates than those using the two tobacco-flavored pods (odds ratio 1.36, 95% CI 1.04–1.78)
• Among those who continued smoking, 50.9%–62.9% reduced their daily cigarette consumption by at least 50%

What Previous Research Shows: Menthol's Consistent Advantage

The JUUL2 data is not an outlier. Multiple studies, using different methodologies and datasets, have found that menthol-flavored e-cigarettes produce higher switching rates than tobacco-flavored alternatives.

Study 1: The 22,000-Person JUUL Cohort

A large US cohort study published in PMC followed more than 22,000 adult smokers who purchased JUUL products over two years, with up to ten follow-up surveys. The researchers tested their findings under multiple assumptions, including conservative models that treated missing participants as continuing smokers.

Across every method, menthol use was consistently associated with higher rates of complete switching (no cigarette smoking in the previous 30 days). Adults who chose menthol JUUL products were roughly 11 to 15 percent more likely to quit smoking entirely than those who used tobacco-flavored versions. The benefit was strongest among adults who previously smoked non-menthol cigarettes — suggesting menthol's appeal isn't simply about flavor preference, but about offering something different during the transition away from smoking.

Study 2: Vuse Longitudinal Data (LTTS)

Reynolds' Longitudinal Tobacco Use and Transitions Survey tracked 485 adult smokers using Vuse products over twelve months. Vuse menthol products showed a 42.0% complete switching rate at twelve months, with "directionally higher rates of complete switching" and lower cigarettes-per-day among continued smokers compared to tobacco flavors.

Study 3: Randomized Trial in Black and Latinx Smokers

A randomized clinical trial published in PMC (PMC10246471) compared menthol and non-menthol e-cigarettes among Black and Latinx adult menthol cigarette smokers. Both groups achieved high switching rates, with comparable grams of e-liquid consumed. The study found no evidence that menthol e-cigarettes were less effective than non-menthol alternatives for this population — a key finding given that menthol cigarette bans are often justified by concerns about menthol's role in smoking initiation among minority communities.

Why Menthol Might Work Better: The Sensory Hypothesis

While no single study has isolated the mechanism, researchers point to several plausible explanations for menthol's switching advantage:

1. Throat hit and satisfaction: Menthol activates cold-sensitive receptors (TRPM8) in the mouth and airways, producing a cooling sensation that can mask the harshness of nicotine aerosol. JUUL Labs' own behavioral pharmacology data found that Polar Menthol–flavored 18 mg/mL JUUL2 pods were rated as "significantly more satisfying" than menthol-flavored pod-based ENDS with 5% nicotine concentrations — suggesting menthol may enhance perceived satisfaction even at lower nicotine levels.
2. Sensory differentiation from cigarettes: Menthol provides a sensory experience that is distinct from combustible cigarettes, potentially helping smokers mentally separate the two products. The cohort study found the benefit was strongest among non-menthol cigarette smokers, supporting the idea that menthol offers novelty rather than reinforcing existing preferences.
3. Reduced irritation: Germany's Federal Institute for Risk Assessment notes that cooling agents "smooth the inhalation experience" and "reduce throat irritation and coughing." While German regulators cite this as a risk factor (potentially encouraging deeper inhalation), from a switching perspective, reduced irritation may make vaping more tolerable for smokers transitioning away from cigarettes.
4. Craving suppression: Some research suggests menthol's sensory properties may help reduce cigarette cravings through a combination of nicotine delivery and sensory replacement, though this mechanism requires further study.

The Dual Use Problem: Why Complete Switching Is Everything

Here's the catch. The FDA emphasized in its JUUL2 announcement that the health benefit comes from complete switching, not dual use. A July 2026 narrative review published in the journal Cureus explains why.

The review examined laboratory, clinical, and population evidence on vapes, heated tobacco, and oral nicotine pouches. Key findings:

• Adults who switched completely to vaping showed substantial reductions — often 90% or more — in biomarkers of exposure to tobacco-specific carcinogens (NNAL and NNN) compared with continued smoking. These reductions can approach levels observed in non-users.
• Smokers who switched completely showed favorable changes in markers linked to inflammation, blood clotting, cholesterol, and blood-vessel health.
• Dual users — those who continued smoking while also vaping — frequently had biomarker levels and cardiovascular risk similar to exclusive smokers. In some studies, their estimated risk was higher.

This is because cardiovascular risk does not fall in direct proportion to the number of cigarettes smoked. Even low-level smoking carries a surprisingly large share of smoking-related heart disease and stroke risk. Simply cutting down may deliver less protection than smokers expect.

Real-World Consequence: The South Korean Evidence

Two recent South Korean observational studies provide real-world confirmation:

• A 2025 study followed 17,973 smokers who had undergone coronary artery treatment. Over 2.4 years, major adverse cardiac events occurred in 10.8% of switchers vs 17% of continued smokers — an 18% lower risk. Complete switchers also had a 29% lower risk than dual users.
• A 2026 study followed 23,262 adults who smoked when diagnosed with COPD. Those who switched to vapes had a 20% lower adjusted risk of major adverse cardiac and cerebrovascular events than those who continued smoking. However, the study did not find comparable reductions in lung cancer or COPD exacerbations.

Both studies are observational — they cannot prove causation. But they align with the biological evidence: eliminating combustion is where the harm reduction happens.

The Counter-Evidence: What Critics Say

The Duke University Blind Spot (2025)

A 2025 Duke University study published in Nicotine and Tobacco Research highlighted a critical research gap: more than 80% of e-cigarette clinical trials never reported rates of dual use. Of 71 clinical trials reviewed, only 12 reported dual use directly, and just one clearly defined the term. This means much of the evidence base — both for and against e-cigarettes — may be missing the variable that matters most: whether participants actually stopped smoking.

The Flavor Ban Paradox: What Canada Shows Us

If menthol helps more smokers switch, what happens when you ban it? Recent evidence from Canada offers a stark warning.

A 2026 economic analysis of Canadian provinces that implemented strict vape flavor bans between 2018 and 2023 found that cigarette sales rose by nearly 10% on average. Flavored vape sales collapsed almost entirely once restrictions took effect, but a substantial share of consumers returned to combustible cigarettes rather than switching to tobacco-flavored vaping products.

This is consistent with multiple US studies showing that when flavored vaping products are restricted, reductions in vaping are often offset by increases in cigarette smoking. The pattern is clear: demand for nicotine does not disappear — it shifts toward more dangerous products.

Meanwhile, Germany proposed a sweeping menthol vape ban in February 2026 despite acknowledging "no clear data showing menthol vaping leads to greater nicotine absorption or higher health risks." Harm reduction experts warned the ban could undermine smoking cessation in a country where smoking rates remain stubbornly high.

Limitations: What This Evidence Can't Tell Us

What This Means for Adult Smokers

Here's the honest assessment: if you are an adult who currently smokes cigarettes, the evidence suggests that switching completely to an FDA-authorized vaping product can substantially reduce your exposure to harmful chemicals. The menthol-flavored versions appear to produce higher switching rates than tobacco-flavored alternatives across multiple studies.

But the key word is completely. Dual use — continuing to smoke while also vaping — does not provide the same degree of health benefit. The FDA, the cardiovascular review, and the biomarker evidence all converge on this point: the harm reduction happens when combustion stops, not when it's reduced.

This is not a medical recommendation. It is a summary of what the current evidence shows — and what it doesn't. If you are considering switching, talk to your healthcare provider about what approach is right for your individual circumstances.

The Bigger Picture: Science vs Policy

The tension between menthol's switching advantage and its youth appeal is at the heart of the FDA's regulatory calculus. The agency's JUUL2 authorization represents a specific choice: the adult benefit outweighs the youth risk, for this specific product, with these specific access-control features (age-gated app, device lock, Pod ID authentication).

But this is a product-by-product determination. The FDA has stated that PMTAs are reviewed on a case-by-case basis, and the JUUL2 reasoning does not automatically transfer to other menthol products or to flavors beyond menthol.

The broader policy question is whether regulators can build frameworks that capture menthol's switching benefit for adults while minimizing youth access. Canada's experience suggests that blunt flavor bans may be counterproductive — pushing smokers back to cigarettes. The JUUL2's technology features (age verification, device locking) represent one possible answer, but their real-world effectiveness remains to be demonstrated.

What is clear from the evidence: the most important variable is not flavor. It is whether the smoker switches completely. Any policy or product that facilitates complete switching — regardless of flavor — is likely to produce greater public health benefit than one that doesn't.

Sources & Further Reading